mshealthcare > chemotherapy
Posted on:

BRYXTA 100 ML INJECTION VIAL: PATEINT GUIDE FOR CANCER TREATMENT

Bryxta 100 mg/4 ml injection is a targeted cancer therapy medication containing Bevacizumab , used to treat various cancers, including colorectal, non-small cell lung ,kidney ,ovarian and cervical cancers. It inhibits tumor growth by blocking vascular endothelial growth factor (VEGF) ,which prevents the formation of new blood vessels that feed tumors. It is a monoclonal antibody used to treat metastatic breast cancer, non-small cell lung cancer ,kidney cancer ,cervical cancer ,epithelial ovarian, Fallopian tube or primary peritoneal cancer ,cancer of colon and rectum.

 

WHY IS TARGETED THERAPY IMPORTANT IN CANCER TREATMENT?

Targeted therapies are crucial in modern cancer treatment by offering precision medicine that attacks specific genetic mutations or proteins driving tumor growth , rather than killing all rapidly dividing cells like chemotherapy . this approach improves survival rates -often extending life beyond 5 years for advanced cancers -while causing fewer side effects and improving quality of life. These therapies specifically identify and disrupt cancer cells, sparing most healthy cells from damage.

Targeted therapies work by blocking signals that tell cancer cells to grow, inhibiting new blood vessel formation and delivering toxins directly to cancer cells. They are used based on the molecular profiling of tumor, often enabling treatment when conventional chemotherapy fails. When a cure is not possible, targeted therapies can often manage cancer as a chronic, stable disease.

 

WHAT IS BRYXTA?

Bryxta is a bio similar bevacizumab (400 mg/100 mg) manufactured by Zydus life sciences ,used as an anti-cancer (oncology) injection to treat various cancers like lung, colorectal, breast and ovarian cancer. It acts by inhibiting VEGF to stop tumor blood supply . it is a prescription-only, refrigerated injection administered by healthcare professionals.

It is a targeted anticancer ,vascular endothelial growth factor (VEGF) inhibitor, classified as a recombinant humanized monoclonal antibody. It works by binding to VEGF to prevent the formation of new blood vessels that feed tumor growth.

Key classification:

  • Active ingredient: Bevacizumab
  • Therapeutic class: anti -neoplastic agent (anti-cancer)
  •  Pharmacological class: VEGF Inhibitor /anti-androgenic agent
  • Mechanism of action: monoclonal antibody that inhibits VEGF, ‘’starving’’ tumors of nutrients and oxygen.
  •  Schedule : schedule H (prescription only)
  • Administration: intravenous (IV) infusion only, administered by a healthcare professional.

 Mechanism of action: Bryxta is used in treating various cancers ,including metastatic colorectal cancer, non-squamous non-small cell lung cancer ,galioblastoma and renal cell-carcinoma.

 

WHAT ARE THE MEDICAL USES OF BRYXTA INJECTION?

Baryxta is a targeted cancer therapy used to treat various advanced cancers-including colorectal, non-small cell lung cancer ,kidney ,ovarian ,cervical and brain -by inhibiting blood vessel growth to tumors . it is typically administered via intravenous infusion alongside chemotherapy to slow cancer progression.

 

Following are the medical uses of Baryxta injection(bevacizumab)

1. Treatment of colorectal cancer

Bryxta injection is a targeted immunotherapy used to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF) ,which starves tumors of blood supply. It is administered via intravenous infusion in combination with fluropyrimidine-based chemotherapy. It is crucial for treating advanced , spreading cancers. It is not a self-injection, it must be administered by a qualified healthcare professional in clinic or hospital setting.

2. Treatment of lung cancer

Bryxta injection is a targeted therapy used to treat advanced non-small cell lung cancer (NSCLC) by inhibiting tumor blood vessel growth . usually paired with chemotherapy, it helps shrinks tumors or slow their progression . it is administered via infusion in a hospital setting. It is used in combination with platinum-based chemotherapy for advanced or metastatic NSCCL.

3. Treatment of kidney cancer

Bryxta injection is an anti-cancer, anti-androgenic medication used in treating various cancers, including kidney cancer by restricting the blood supply required for tumor growth.it works by inhibiting VEGF, usually administered via intravenous infusion in combination with other treatments by a healthcare professional. It is used as a part of combination therapy for treating kidney cancer , particularly metastatic or advanced cases. It must be administrated by a qualified healthcare professional in a hospital or clinic setting via an iv infusion.

4. Treatment of cervical and ovarian cancers

Bryxta injection is an anti-androgenic targeted therapy used for advanced cervical cancers by inhibiting tumor blood supply. In combination with chemotherapy, it is indicated for persistent/recurrent/metastatic cervical cancer and platinum-sensitive /resistant ovarian cancer. It is administered via iv infusion by healthcare professionals.

5. Often used in combination with chemotherapy

Bryxta injection is a prescription anti-angiogenic medication used in combination with platinum-based or other chemotherapy regimes to treat various advanced cancers, including non-small cell lung cancer (NSCLC) ,colorectal ,ovarian ,cervical and kidney cancers.it act by inhibiting VEGF to starve tumors of blood supply, improving survival rates when paired with chemotherapy. It is not a chemotherapy agent itself, but an immunotherapy that boost the efficacy of chemotherapy.

 

WHAT ARE THE BENEFITS OF BRYXTA 100 ML INJECTION?

Bryxta 100 mg injection is a targeted anti-cancer therapy that inhibits the growth of new blood vessels (angiogenesis) to tumors, effectively starving them of nutrients and oxygen. It is primarily used to treat various advanced cancers, including colon, rectum,lung ,kidney, brain ,cervical and ovarian cancers.

Benefits of Bryxta 100 ml injection are:

1. Slows tumor growth by blocking blood vessel formation

Bryxta 100 mg injection is an anti-cancer medication that contains Bevacizumb . it is used to treat various advanced cancers by stopping the growth of new blood vessels that feed the tumor. By blocking the vascular Endothelial Growth Factor (VEGF) protein, bryxta starves cancer cells of necessary nutrients and oxygen ,causing the tumor to shrink or cease development. It is not recommended for use in pregnant women as it can harm the fetus, and effective contraception must be used for six months after treatment.

2. Enhances effectiveness of chemotherapy

Bryxta 100 mg injection is designed to be used in combination with chemotherapy to enhance its effectiveness in treating various metastatic cancers. It works by targeting the blood supply to the tumor, rather than acting as a traditional chemotherapy agent itself. It works by targeting the blood supply to the tumor ,rather than acting as a traditional chemotherapy agent itself.

3. Helps manage advanced cancers

Bryxta 100 mg injection is an anti-cancer medication containing Bevacizumab, which is used to manage various advanced or metastatic cancers. It works as a targeted therapy that inhibits the formation of new blood vessels within tumors, starving them of oxygen and nutrients to slow their growth.

 

Conclusion: Bryxta 100 mg injection is a potent, targeted anti-cancer medication used to treat various advanced or metastatic cancers by inhibiting tumor blood vessel growth. It act as an anti-androgenic agent ,targeting vascular endothelial growth factor (VEGF) .it is used for metastatic colorectal, non-small cell lung, kidney, brain ,cervical ,ovarian, Fallopian tube and liver cancers. It is a prescription drug administered by healthcare professional via IV infusion and is not recommended for children under 18.

 

FREQUENTLY ASKED QUESTIONS(FAQ) :

 

QUESTION: IS Bryxta a chemotherapy drug?

Bryxta is an anti-cancer targeted therapy drug containing

,bevacizumab  designed to inhibit blood vessel formation to starve tumors. While technically an anti-androgenic agent . it is frequently used in combination with chemotherapy to treat various cancers, including lung, colorectal, brain ,kidney and ovarian cancers.

QUESTION: How long does treatment last?

Bryxtra treatment is generally continued for as long as the cancer is controlled and side effects remain manageable. There is no fixed end date, treatment continues as long as it is effective and tolerated. It is commonly used in combination with other chemotherapy drugs.

 

QUESTION: Can Bryxta cure cancer?

No, Bryxta is an anti cancer medication used to treat various types of advanced or metastatic cancer in combination with other therapies. It does not cure cancer. It is typically a part of comprehensive treatment plan and is not a universal cure for the disease. There is currently no universal cure for all types of cancers.

REFRENCES:

1.https://www.apollopharmacy.in/medicine/bryxta-100mg-4ml-inj?srsltid=AfmBOoq2yUd8APYOXgCANk1uLX0XVLTmOrL-HhoE1jix-f8yhPp_8-YX

2.https://www.truemeds.in/medicine/bryxta-100-mg-injection-4-ml-tm-inon2-000960

3.https://www.practo.com/medicine-info/bryxta-100-injection-45724

Posted on:

UNDERSTANDING BORTEZOMIB THERAPY WITH BORVIZ 2 mg

WHAT IS BORVIZ 2 MG?

Borviz 2 MG injection is a chemotherapy medication classified as a protease inhibitor, contains the active ingredient Bortezomib . it is prescribed for the treatment of multiple myeloma,a cancer of plasma cells in the bone marrow ,and mantle cell lymphoma, a less common cancer affecting the lymph nodes. It is an anti neoplastic agent that interferes with the growth of cancer cells ,which are eventually destroyed by the body.

DRUG CLASSIFICATION:

  •  Action class: proteasome inhibitors
  • Therapeutic class : anti-neoplastic /targeted therapy
  •  Chemical class: phenylalanine derivative
  •  Active ingredient: Bortezomib
  •  Usage: use in the treatment of multiple myeloma and mantle cell lymphoma
  •  Administration: intravenous or subcutaneous injection by a healthcare professional.

It is a cytotoxic agent primarily used for managing blood cancers, particularly when stem cell transplantation is not suitable.

WHAT ARE THE MEDICAL USES OF BORVIZ 2 MG INJECTION?

Borviz 2 mg injection contains Bortezomib, a protea some inhibitor used to treat adults with multiple myeloma (bone marrow cancer) and mantle cell lymphoma (a type of blood cancer affecting lymph nodes) . it acts by blocking protein breakdown in cancer cells, forcing them to die ,and is often used in combination therapy.

Some of the medical uses of Borviz 2 mg injection are:

1. Treatment of multiple myeloma

      Borviz 2 mg injection is a targeted cancer therapy used to treat multiple myeloma-a bone marrow cancer-by inhibiting protectorates to induce cancer cell death. It is administered by a healthcare professional ,often in combination with other medicine for both newly diagnosed and previously treated patients.

  •  Indications: used for treating multiple myeloma and mantle cell lymphoma. It is utilized in induction therapy before stem cell transplants for patients who cannot undergo a transplant.
  •  Mechanism of action: As a protease inhibitor, it interferes with the degradation of intercelluar proteins, causing an accumulation that leads to cancer cell death.
  •  Administered: it is given by intravenous (IV) or subcutaneous (under the skin) injection by a doctor.
  • Common side effects : low platelet count, peripheral nephropathy ,nausea, vomiting ,fatigue , constipation and fever.
  •  Precautions: requires monitoring of blood counts and organ function . it is not recommended during pregnancy or breastfeeding.
  • Management : patients are often advised to stay hydrated and avoid driving if they feel dizzy or tired.

2. Treatment of mantle cell lymphoma

 Borviz 2 mg injection is a targeted therapy used to treat mantal cell lymphoma (MCL) ,specifically in patients who have not responded to or have relapsed after other therapies. As a proteasome inhibitor, it destroys cancer cells and is often combined with rituximab and chemotherapy administered by a healthcare professional.

  •  Mechanism: it act as a protoseome inhibitor,interfering with the proteosonmes in cancer cells, which leads to their death and stops further growth.
  • Administration: it is administered either intravenously (in to the vein) or subcutaneously (under the skin) by a qualified healthcare professional.
  • Combination therapy : in MCL treatment, Borviz is often used in combination with other chemotherapy agents and rituximab, particularly for patients not suitable for stem cell transplantation.
  • Common side effects: common side effects include nausea, vomiting, diarrhea, peripheral neuropathy ,constipation etc.
  •  Precautions: it is not recommended during pregnancy or breastfeeding . it may cause dizziness, so caution is advised when driving.

3. Used as a part of combination chemotherapy regime

Borviz 2 mg injection is a protea some inhibitor used in chemotherapy to treat multiple myeloma and mantle cell by inducing cancer cell death. It acts by blocking protein degradation, causing stress that kills malignant cells. It is often used in combination with other agents like dexamethasone or thalidomide.

  • Multiple myeloma: used for treating myeloma, especially in patients who have not received prior treatment and are ineligible for blood stem cell transplantation.
  • Mantle cell lymphoma: used for patients with this type of non-hodgkins lymphoma who have received at least one prior therapy.
  •  Mechanism: as a protesome inhibitor, it breaks down essential protein in cancer cells, forcing them to undergo apoptosis .

WHAT ARE THE BENEFITS OF BORVIZ 2 MG INJECTION?

 

Benefits of Borviz 2 mg injection are:

1. Helps slows the growth of cancer cells

   Borviz 2mg injection, containing the active ingredient Bortezomib, is a protesome inhibitor used to treat multiple myeloma and mantle-cell lymphoma by slowing cancer cell growth and promoting their death. It works by interfering with proteosomes to induce apoptosis in cancer cells. It is primarily used for multiple myeloma and mantle cell lymphoma. As a protosome inhibitor, it interrupts the normal degradation of proteins within cancer cells, causing a toxic buildup that leads to cell death.

2. Improves treatment outcomes in multiple myeloma

       Borviz 2 mg injection ,which contains Bortezomib as its active ingredient, is a highly effective ,FDA approved proteasome inhibitor used to treat multiple myeloma and mantle -cell lymphoma. It significantly improves treatment outcomes by halting the progression of cancer cells, increasing survival rates and inducing deep responses in both newly diagnosed and refectory patients. As a proteasome inhibitor, it disrupts the 26s proteosome in cancer cells, leading to an accumulation of toxic proteins,which causes the cancer cells to undergo apoptosis.

3. May be combined with other cancer medicines for better results

  Borviz 2 mg is frequently combined with other medications like dexamethasone, melphalan, prednisone or rituximab to enhance efficiency . the treatment is administered by a professional ,often resulting in better outcomes than single agent therapy. It is often combined with dexamethasone, or with melphalan and prednisone. It is commonly combined with rituximab and other chemotherapy drugs. They are used with dexamethonase and thalidomide prior to stem cell transplantation.

      CONCLUSION: Bortezomib therapy is a highly effective, standard of care proteasome inhibitor for treating multiple myeloma and mantle cell lymphoma ,significantly improving patient survival rates. Subcutaneous administration is preferred for better tolerabilty, with manageable side effects like peripheral nephropathy and thrombocytopenia making it a cornerstone treatment for both newly diagnosed and relapsed patients.

FREQUENTLY ASKED QUESTIONS(FAQ)

QUESTION: IS BORVIZ A CHEMOTHERAPY DRUG?

Borviz is a targeted chemotherapy injection used to treat multiple myeloma and mantle-cell lymphoma by stopping cancer cell growth. it is important to maintain hydration during treatment and inform doctors of any pre-existing liver, kidney or heart conditions.

QUESTION: HOW MANY TREATMENT CYCLES ARE REQUIRED?

Treatment is administered in cycles, with the number of cycles depending on whether the cancer is newly diagnosed or relapsed. Generally several cycles are recommended, which may be adjusted based on the patient’s response to treatment. Treatment typically involves a series of cycles, often continuing based on clinical response.

QUESTION: CAN IT CURE MULTIPLE MYELOMA?

Borviz is a potentproteasome inhibitor used to treat multiple myeloma by inhibiting the growth of cancer cells, often leading to remission or significantly slowed disease progression. While it is not considered a permanent cure, it is highly effective in

managing newly diagnosed and relapsed cases.

REFRENCES

1.https://health29.in/item/borviz-2mg-injection-lyophilized-borviz%202mg%20injection%20%28lyophilized%29

2.https://www.apothecare.in/products/borviz-2mg-injection

3. https://www.tradeindia.com/products/borviz-2mg-inj-c7933103.html

Add to cart